As noted in this manuscript, CS1-directed radioligand therapy increases CD8+ T-cell infiltration and PD-L1 expression, suggesting the potential for combining TRT with immunotherapies to enhance anti-tumor responses [126]. The gene discussed is CD8A; the disease is neoplasm.